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Abstract 
 
Existing research on the patterns and risk factors of drug use and how they vary by age 
and location in Turkey is limited. The paper will examine the drug treatment options within 
Turkey as well as the socio-demographic characteristics, behaviors, treatment history, and 
identified correlates of lifetime and current injection drug use of Turkish citizens who were 
admitted to inpatient substance use treatment at public and private facilities in Turkey during 
2012 and 2013. Of the 11,247 patients at the 22 public treatment centers in 2012-2013, a 
majority were male, lived with family, were unemployed, and had an average age of 27 years. 
Significant predictors of injection drug use included being homeless, having higher education, 
heroin as a preferred drug, having a longer duration of drug use, and prior drug treatment. With 
this information, greater prevention and intervention efforts can be made to reduce the transition 
to drug use among the youth population as well as improve access to a variety of tailored 
treatment options.  
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Introduction 
 
Substance use disorder is a complex yet treatable disease that seldom exists as an 
independent entity and frequently occurs alongside a number of comorbidities like HIV/AIDS, 
HCV, and other mental disorders. Turkey currently faces the difficulty of instituting an effective 
nation-wide program that combats addiction due to the range of physical, psychological, and 
social issues substance use embodies. The Turkish Ministry of Health provides national 
treatment for drug use through 22 existing governmentally funded Research, Treatment and 
Training Centers for Alcohol and Substance Addiction (AMATEM centers) that are located in 13 
of the 81 provinces of Turkey (TUBIM, 2012). With so few facilities, inconsistencies and 
limitations in obtaining addiction treatment are widespread. Moreover, the extensive ties 
between addiction, society, and environment are often not reflected in current treatment models.  
Alongside the difficulty of instituting effective and comprehensive drug treatment 
options, Turkey is facing an increased number of individuals seeking treatment for heroin use for 
the first time, one of the most addictive illicit drugs, with an almost 45 percent increase from 
2004 to 2009 (Barrio et al., 2013). Geographically speaking (see Figure 1), Turkey is located 
within a transit route that makes it extremely conducive to varied markets, especially so for the 
trade and utilization of narcotics like that of heroin (Akgoz et al., 2007). The drug trafficking 
route originates in Afghanistan, a country that contributed to 93% of world’s opium supply in 
2007, and extends to Europe (Todd et al., 2007; WHO, 2008) Due to this, Turkey acts as a 
middleman for the transit of drugs, with its vicinity to Afghanistan and borders next to the Black 
Sea and the Caspian Sea port – both maritime locations increasingly utilized for the transport of 
illegal drugs (Zaitseva, 2002). Although a susceptible location to drug trafficking routes, Turkey 
is also a culturally unique country. Due to its geographical placement, the nation has 
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sociocultural ties to both Middle Eastern and European countries and values. Turkey is a 
secularized country, however still faces regional differences between local, traditional beliefs 
and Westernized practices. Such variability within population demographics, culture, 
urbanization, wealth, and income inequality can contribute to variant risk for drug use (Galea et 
al., 2003; Baumann et al., 2007). Even with such distinct country characteristics, current research 
on the frequency, trends and associated risk factors of drug use within Turkey are far and few in 
between—usually focusing in single cities or provinces (Akgoz et al., 2007; Barrio et al., 2013).  
Studies that have been conducted in Turkey report an increase in polysubstance use, a 
higher prevalence of cannabis use, and a reduction in the mean age at first heroin use (Akgoz et 
al., 2007; Demirci et al., 2014). Such growing trends are notable to recognize as they indicate 
that drug use is becoming more common within Turkey and seen amongst younger cohorts.  
The two goals of this thesis are to: 1) Conduct a comprehensive overview and analysis of 
Turkey’s current drug treatment offerings and 2) Describe and identify the characteristics of 
inpatients admitted to public and private facilities in Turkey from 2012 to 2013. Analyzing 
Turkey’s treatment set up and organization as well as data collected on individuals admitted to 
inpatient treatment are critical first steps in further understanding a vulnerable subset of Turkey’s 
population (people who use drugs), creating improved patient care models, and identifying key 
areas for prevention strategies.  
Drug Treatment in Turkey 
 AMATEM centers provide both outpatient and inpatient options; however outpatient 
services are used at much higher frequencies than inpatient options (TUBIM, 2012). Turkey’s 
2012 Annual National Drug Report (TUBIM) states that approximately 150,000 patients seek 
outpatient treatment within the 22 AMATEMs (TUBIM, 2012). According to our data collection 
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in 2012 to 2013, 11,247 utilized inpatient treatment and 663 utilized private centers. 98% of 
Turkish citizens are covered by its general health insurance, which in accordance with Turkey’s 
Law on Social Security and General Health Insurance, covers all services and costs provided at 
AMATEMs (TUBIM, 2012). Only 1.5% of Turkish citizens will utilize additional supplementary 
private insurance that assists in covering costs at private facilities (Drechsler & Jutting, 2007; 
Colombo & Tapay, 2004). Usually, PWUD that do seek private treatment facilities do so for the 
desire of anonymity and VIP services. However, such private treatment includes additional fees 
that either are covered by private insurance or paid out of pocket. Currently, the private sector for 
drug use treatment in Turkey has been growing because drug users are fearful of disclosing their 
status at the public AMATEMs. Since patients are utilizing the general health insurance when 
accessing AMATEMs, doctors must report all cases, including the patient’s name, to a national 
registry (Ay & Karabey, 2006). However, private clinics must report their caseload, but can 
preserve the anonymity of their patients and are not legally required to include patient names (Ay 
& Karabey, 2006). Further, when admitted to an AMATEM center, the patient name and file can 
be accessed by any national body, including those that will determine whether a patient is able to 
pursue certain professions. Such policies can lead to stigmatization, fear of disclosure/lack of 
confidentiality, and issues with finding jobs.  
 Treatment procedures and detoxification therapy are vital to successful programs and the 
overall relapse of the clinic’s patients. Opioid assisted therapy is a growing global trend in the 
past years for opiate drugs, which are naturally derived from opium. Opioids, the most common 
being buprenorphine and methadone, are synthetically derived from opiates (Whelan & Remski, 
2012). Opioids are considered agonists—mimicking the biological effects of opiates, like the 
rush of endorphin and encephalin, yet at a lesser level than opiates (Whelan & Remski, 2012). 
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The standard medication-assisted treatment (MAT) approach in AMATEM and private clinics is 
solely through the application of Suboxone, a buprenorphine/naloxone combination oral 
medication (EMCDDA, 2014). Buprenorphine is a partial opioid agonist that has been lauded by 
many scientists for a lower potential for abuse and lower overdose risk than that of the 
methadone treatment option (Whelan & Remski, 2012). Naloxone is an opioid antagonist that 
partially blocks the addictive effects of opiates (NIDA, 2014). According to the World Health 
Organization (WHO) the most successful approaches to drug addiction treatment is through 
methadone maintenance and buprenorphine substitution therapies, yet methadone approaches are 
considered even more effective. Methadone is currently not offered in Turkey due to legal and 
policy considerations where methadone is considered a full opioid agonist (whereas 
buprenorphine is a partial agonist). Methadone is reported as too close in bodily response to 
PWUD’s original substance of addiction—an opiate—thus essentially replacing a substance with 
another substance. Methadone and buprenorphine, which were historically used for pain 
management, mimic the patient’s psychoactive substance of choice (i.e. opium or heroin) and are 
administered by healthcare workers during replacement treatment (WHO, 2008). After a series of 
time, the patient is slowly weaned off the methadone and/or buprenorphine treatment.  
Alongside the medical substitution detoxification process, other psychological 
interventions are applied at Turkish treatment facilities, some of which include: motivational 
interviewing, cognitive behavioral therapy, and group therapy. However, even with these public 
and private facilities, according to TUBIM, nearly half of the individuals admitted to 
AMATEMs return for additional treatment—a trend that must be comprehensively identified and 
understood so as to lower rate of relapse (TUBIM, 2012). 
 
 8 
HIV/AIDS and HCV in Turkey 
At the end of 2013, there were approximately 1,350 reported HIV cases and 
approximately 100 reported AIDS cases in Turkey (Gorkem, 2015). There is an exponential 
upward trend in incidence of HIV/AIDS cases in the last decade (as seen by Figure 2). Turkey 
has one of the lowest occurrences of the virus, however the fact remains that two-thirds of the 
infections occurred after 2003—thus illustrating an aggressive growth in HIV diagnoses. In 
2013, the Turkish Ministry of Health reported HIV rates amongst intravenous drug users at 1% 
(See Figure 3). Further, in 2013, 51% of those diagnosed with HIV had an “unknown” route of 
transmission, thus heralding the need for greater systematic reporting of HIV cases. Patients may 
also fear stigmatization when reporting their true route of transmission or have a lack thereof of 
education on how HIV is transmitted (Gorkem, 2015). Such a large percentage must be 
addressed and decreased, since Turkey’s HIV positive population is predominantly young. 
Approximately 25% of the HIV positive population is aged 25 to 35 years old (Duygu, 2016). 
With such a young age of occurrence, HIV/AIDS will have to be managed by Turkey’s 
healthcare system well into the future.  
Another common related risk with injecting drug use is the prevalence of the Hepatitis C 
Virus (HCV). HCV can be transmitted through blood transfusion of unscreened donors, injection 
drug use, unsafe therapeutic injections, and other healthcare procedures. However, the majority 
of recent global HCV reports occur primarily form injection drug use (Shepard et al., 2005). 
Treatment options for HCV infection are available, however service uptake is low, particularly 
among people who inject drugs (PWID) -- leading to a substantial burden of HCV-related 
morbidity and mortality in PWID populations, including liver failure and related complications 
(Bruggmann et al., 2015). Besides the immediate burden of HCV infection to the patient, HCV is 
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transmitted ten times more efficiently than HIV when intravenous practices are present 
(Strathdee et al., 2002) Therefore, high HCV rates are important indicators that may also 
foreshadow future HIV epidemics given the similarity of the risky behaviors and injection 
practices of PWID that spread both infections (Todd et al., 2007; Kuo et al., 2006). 
According to TUBIM, of the 866 injecting drug users receiving inpatient care in 2011, 
48.6%, or 351 of the 722, were tested positive for Hepatitis C (TUBIM, 2012). As age increases, 
the risk for contracting HCV grows. HCV positivity was at 65.15% for people who were 
injecting drugs for more than 10 years (TUBIM, 2012). With heightened and longer drug use, the 
higher the chance of contracting risk related diseases like HCV or HIV/AIDS. The prolific 
growth of HIV/AIDS in such a short time span and the high prevalence of HCV coincide with 
the need for greater coordinated steps in preventing and treating drug use and related risks. 
Treatment programs for substance use need to focus upon comprehensive, community-based care 
that caters not only directly to substance use, but also related risks that arise with addiction.  
Objectives of the Study 
With this distinct combination of unique characteristics and demographics within Turkey, 
the objectives of this study are to describe the characteristics of individuals admitted to both 
public and private facilities for inpatient drug treatment in Turkey from 2012 to 2013, and to 
identify the correlates of PWID both in their lifetime and in the past month. Other aims include 
identifying the correlates of needle sharing and HCV infection so as to better understand the 
risky practices among PWID in Turkey and their contribution to the spread of HCV and HIV. 
Comprehensively analyzing and disseminating data collected on individuals admitted for 
treatment and correlates of HCV and HIV among people who use drugs (PWUD) in Turkey is a 
critical first step in understanding what can be done to better assist PWUD, create tiered 
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preventative measures for PWUD and PWID, halting the transmission of HCV and HIV, and 
identifying holistic and need-specific models to treatment.  
Methods and Study Participants 
 Turkish citizens that were admitted to inpatient AMATEM centers or at private clinics in 
Turkey in 2012 or 2013 were part of the statistical dissemination. AMATEM centers are public 
and are predominantly located in major cities of Turkey. All services at public facilities, as 
aforementioned, are provided free of cost by Turkey’s Social Security Institution (TUBIM, 
2012). TUBIM reports that approximately 150,000 patients utilized outpatient options at the 22 
public centers; therefore inpatients at AMATEMs are a distinct minority of all individuals 
seeking treatment in Turkey.  
 Information on the inpatients (socio-demographic characteristics and drug use behaviors) 
were obtained by clinic staff through a modified version of the Treatment Demand Indicator 2.0, 
which is created and supported by the European Monitoring Center for Drugs and Drug 
Addiction (EMCDDA, 2000). Buprenorphine and methadone treatments are not available in 
Turkey and such questions were not included in the questionnaire. Socio-demographic 
characteristics included gender, age, number of years of education, living situation (alone, with 
family, with friends, in a shelter, or homeless), and employment status (regular job, temporal 
employee, unemployed, or other).   
History of drug use and current drug using behaviors were also obtained via the 
questionnaire, including age at first use, frequency of use in the past month, and preferred route 
of administration (injection, smoking, snorting, and eating or drinking) for up to three drugs, 
including the primary substance of choice. Drug types included heroin, other opioids (e.g., 
meperidine and morphine), cocaine, cannabis, synthetic cannabis (e.g., bonzai), club drugs (e.g., 
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ecstasy, ketamine, methamphetamine), prescription medications (e.g., alprazolam, diazepam, 
zolpidem), and inhalants (e.g., glue, paint thinner). From this information, we identified 
individuals who had used multiple types of drugs in the past month. We also calculated each 
individual’s duration of drug use based on the minimum age of first use of any reported 
substance. Individuals were also asked if they had ever injected a drug, and whether they had 
injected in the past 30 days. Further, information was obtained about whether the individual had 
received inpatient drug treatment in any treatment center previously.  
Individuals who reported ever having injected a drug were questioned about their age at 
first injection, whether they had ever shared a syringe, and whether they had injected and shared 
a syringe in the past 30 days.  Finally, individuals were tested for Hepatitis B virus (HBV), 
Hepatitis C virus (HCV), and Human Immunodeficiency Virus (HIV). 
 Turkey is divided into seven geographic regions, as depicted in Figure 4. The public and 
private treatment centers were grouped by location into these seven locations: Marmara 
(including Istanbul, Bursa, and Edirne), Aegean (including Izmir, Manisa, and Denizli), 
Mediterranean (including Antalya, Adana, and Mersin), Central Anatolia (including Ankara, 
Konya, and Kayseri), Southeast Anatolia (including Gaziantep and Diyarbakir), Black Sea 
Region (including Samsun), and East Anatolia (including Elazig). Istanbul, Izmir, and Ankara 
have multiple treatment centers. Figure 4 further labels these general locations of the private and 
AMATEM clinics as per the red dots.  
 With the assistance of epidemiologists, analyses on the survey data were conducted using 
chi-square tests for categorical variable and ANOVA for continuous variables. Multiple logistic 
regression models were estimated that predicted lifetime and current injection, including 
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predictors that were at least marginally significant, with a p-value less than .10 in bivariable 
analyses.  
Characteristics of People Who Use Drugs 
Using data from public and private facilities, we identified key characteristics of 
substance users in Turkey who sought inpatient treatment, including differences in drug-using 
behaviors by age. As seen in Table 1, within AMATEM centers, a majority were male (94.3%), 
had been living with family (94.7%), and were unemployed (64.4%); the average age of 
individuals was 26.6 years old. Heroin was the most commonly reported drug of choice (75.4%), 
followed by cannabis (13.2%). In contrast, private clinic patient characteristics included a higher 
proportion of patients that were female, aged 11-17 years old, had a regular job, used cannabis or 
synthetic cannabis as their primary drug, reported snorting as their primary route of 
administration, and had previously received drug treatment (Table 1). 
Characteristics of substance users admitted for inpatient drug treatment in this study were 
similar to those observed in other countries. In studies done in South Africa, Malaysia, China, 
and Egypt, most users were also male, unemployed, homeless, utilized heroin as the drug of 
choice, and were between the age of 20 and 30 (Hasan et al., 2009; Saban et al., 2014; WHO, 
2009).  
HCV, HBV and HIV 
HCV was reported in 47.1% of the patients who ever injected drugs and 51.9% of those 
that injected in the past 30 days (Table 6). This high prevalence of HCV outreaches reports of 
HCV seen in Afghanistan (36.6%) and New York City (42-52%) (Todd et al., 2007; Des Jarlais 
et al., 2003). However, in Pakistan and Iran, HCV rates are about 30% higher with reports at 
88% and 80% (Kheirandish et al., 2009; Kuo et al., 2006). These rates are notable since Pakistan 
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and Iran are border nations to Afghanistan—where some of the largest opioid production occurs 
in the drug market (WHO, 2008). As border nations, these countries are key in the selling and 
transporting illegal drugs along this route. Turkey, albeit further from Afghanistan, is part of the 
drug route and seems to be showing a mirrored growth of HCV to that of Pakistan and Iran.  
HBV, another comorbidity that can be present in injection drug users, was found amongst 
the inpatients at 6.2% for those who ever injected drugs and at 5.9% for those who injected in the 
past 30 days. These trends follow other prevalence rates found in India (6%), Afghanistan 
(6.5%), and New York City (6%) (Todd et al., 2007; Panda et al., 2002).  
HIV was quite rare amongst lifetime PWID, with only 15 cases, thus a prevalence of 
.34% (Table 6). Regarding comorbidity between infections among lifetime PWID who were 
HBV-positive, 50.4% were also HCV-positive. For those who were HIV-positive, 53.3% were 
also HCV-positive. As noted earlier, high HCV trends have a tendency to foreshadow future HIV 
epidemics. Although HIV is currently at a low reported rate for PWID, it is still ever important to 
continue surveillance of this disease since heroin use is continuing its upward trend within 
Turkey, which is vastly associated with injection drug use and dirty needle sharing. Further, 
harm reduction programs like needle exchange programs are illegal in Turkey, thus access to 
sterile needles is extremely difficult. Further research needs to examine whether Turkish PWID 
partake in other risky behaviors like unprotected sex that could make them more vulnerable to 
contracting HIV in other situations besides injection drug use.  
Injection Drug Use and Needle Sharing 
Significant predictors of being a PWID included being homeless, being a temporal 
employee or unemployed, having higher education, using heroin as a preferred drug, having a 
longer duration of drug use, sharing needles, and receiving prior drug treatment (Tables 3 & 4).  
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As seen in Table 3, 40.4% of the individuals treated in AMATEMs reported ever 
injecting drugs, whereas 33.7% injected in the past 30 days. These trends are consistent with 
other studies of PWID who were admitted for substance use treatment; for example, 45% of drug 
users in a study conducted in Finland administered their primary dug of choice intravenously 
(Onyeka et al., 2012). The characteristics of PWID in our study were similar to other studies 
conducted in the Middle East. In Afghanistan and Pakistan a higher proportion of PWID were 
male, unemployed, utilized heroin as a drug of choice, and were either homeless or displaced 
(Kuo et al., 2007; Sherman et al., 2005; Todd et al., 2009).  
Needle sharing is one of the strongest predictors seen in our study for increased 
likelihood of HCV (Table 7). When examining a cohort of PWID with clean needles, one report 
found that the likelihood of HCV transmission drops to 4% per year amongst those who never 
shared needles (Crofts et al., 1999). In contrast, another study of past drug users that were 
negative for HCV, rapidly became HCV positive within 1 year of first injection (Hien et al., 
2001). We also found that HCV prevalence increased with greater duration of drug use, with 
62.7% of all PWID that have been using for at least 10 years reporting HCV infection.  
Further predictors of needle sharing found in our study include being of younger age, 
being less educated, and of lower socioeconomic status (Table 6). Being unemployed or not 
having the means to afford clean needles has proven to be associated with sharing needles in 
several studies (Magura, 1989; Valente et al., 2002). PWID within lower socioeconomic statuses 
are forced to determine between buying more drugs or new equipment—due to their addiction, 
drugs tend to be the foci of choice (Magura, 1989). Further, in concurrence with our study, age is 
highly reflective of increased injection as many reports find needle sharing to be a frequent 
practice amongst the youth (Hien et al., 2001). More than half of the PWID that shared needles 
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were found to be living with family and a little less than half were found to be living with friends 
and sharing needles. One study amongst a cohort of PWID found that 77% of men’s and 80% of 
women’s social networks had members that used drugs on a daily basis (Sherman et al., 2001). 
In tandem, HCV rates were statistically significant in both living situations for our study. It has 
been found that when using drugs with sexual partners or friends, some PWID reported that they 
worried their friends would feel insulted if they refused to share needles—thus suggesting that 
peer behavior can exacerbate needle sharing and the subsequent contraction of HCV (Magura et 
al., 1989).  
Women Who Use Drugs 
In 2012 and 2013, less than 6% of AMATEM inpatients and less than 10% of inpatients 
at private clinics were women (Table 1). These low percentages of women are similar to those 
observed in other treatment-seeking populations in post-Soviet countries, Iran, and Malaysia, a 
Muslim Asian country, in which 97.6% of PWUD in public treatment were men between 20 and 
30 years of age (Otiashvili et al., 2013; WHO, 2009; Dolan et al., 2011). It is unclear whether the 
small proportion of women utilizing treatment in Turkey reflects a lower frequency of drug use 
among women or reluctance among women to seek treatment due to stigma or other barriers that 
hinder access to treatment (TUBIM, 2012). AMATEM doctors must report all patients, including 
the patient’s name, to a national registry; this lack of anonymity at public centers may be an 
important barrier to treatment access, particularly among Muslim women, who may avoid 
seeking help for drug use due to fear of negative community consequences (Ay & Karabey, 
2006; Cifti et al., 2012).  
To be noted, a higher proportion of women were utilizing private clinic patients (6% vs. 
10%), which may reflect a general increase in private sector drug use treatment in Turkey 
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because PWUD, especially females, are fearful of disclosing their status at public treatment 
centers. Indeed, in a study in multiple Middle Eastern countries, women who use drugs 
(WWUD) reported stigma and discrimination in the forms of social distancing, rejection, 
humiliation and denial of rights as frequent obstacles to treatment services (MENAHRA, 2013). 
By contrast, in the European Union and United States, where female drug users are less 
stigmatized, women comprise 20-40% of those in treatment (Otiashvili et al., 2013). Even in 
China, a country with some of the highest reported heroin use, 17% of inpatients were female, 
with this higher rate most likely attributed to the gender specific treatment options that China 
offers (WHO, 2009).   
Additionally, in public treatment centers, there is a requirement that those who receive 
drug services must also receive HIV tests, while this is not the same in private clinics. Due to the 
potential for stigmatization based on HIV status, this may make private centers even more 
attractive to female drug users. For example, in 2002, home HIV tests were becoming a 
widespread mode for HIV testing amongst women in Turkey (“Woman Attention”, 2002). 
Married women often stated within the article that they feared being labeled as a “woman who 
cheats on her husband” if they were to go to a lab or hospital to receive HIV testing services—
illustrating the types of stigmatization issues in Turkey that bar women from receiving such 
services (“Woman Attention”, 2002). Upon patient stigmatization, the patient can be more likely 
to suffer from self-esteem issues and less likely to engage in the treatment procedure, further 
perpetuating the many risks this vulnerable population faces (Vanable et al., 2006).  
Age Differences and Youth Drug Use 
We also noted striking differences in drug-using behaviors between age groups, which 
highlights the need for intervention and prevention efforts targeted towards adolescents in 
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Turkey. As seen in Table 2, compared to the older individuals in treatment, there were a higher 
proportion of females in the youngest age group (18.8%), as well as individuals living in a 
shelter (8.6%) and reporting being unemployed (75.6%).  
Nearly 42% of the 11-17 year olds receiving treatment reported utilizing heroin as their 
drug of choice (Table 2). In contrast, for adolescents admitted to treatment in the United States in 
2011 only, 14.8% aged 12-14 and 16.9% aged 15-17 used heroin as a primary substance of 
choice (SAMHSA, 2014). Heroin did not even rank in the top two drugs of choice reported by 
15-17 year olds in the US. In further juxtaposition, the misuse of prescription opioids in the US 
has been rising since 2002 (Johnston et al., 2009). One study reports that 6.2% of adolescents 
aged 12-17 used prescription pain relievers for nonmedical use in the U.S. while in Turkey less 
than 0.5% in this age group used prescription medications (SAMHSA, 2015). Similarly, in a 
study conducted in Finland, only 2% of those aged 14 or younger used opiates, and only 28% of 
those aged 15 to 24 used opiates (Onyeka et al., 2012). Within the 11-17 year age group in our 
study, heroin use started at the age of 13 and then increased at each year of age, with nearly 50% 
of 17 year olds reporting heroin as their substance of choice. Initiating heroin use at such a young 
age increases odds for transitioning to injection, developing risky injection practices, contracting 
blood-borne diseases like HIV/AIDS and HCV, and falling victim to drug overdose at earlier 
ages (Barrio et al., 2013; Griffin et al., 2003; Onyeka et al., 2012). Alongside this, we noted that 
50.1% of the 11-17 year old Turkish inpatients used more than one drug per month (vs. about 20-
30% in the older age group), most likely reflecting the experimentation stage among youths who 
are new to substance use, but nonetheless, increasing the odds of developing chronic 
polysubstance use and related harms (Griffin et al., 2003).  
Further, the use of cannabis (29.6%) and synthetic cannabis (7.5%) was also particularly 
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popular among the youngest Turkish inpatients (Table 2). Bonzai, a type of synthetic cannabis in 
Turkey, is becoming a widespread drug of choice with a 19 times increase in bonzai possession 
arrests in Turkey from 2011 to 2012 (Çoban, 2014; Atik et al., 2015; Gurdal et al., 2013). Bonzai 
is a dangerous drug with debilitating effects on the body that can include increased risk of death 
or serious problems in the cardiovascular, neural or digestive systems (Çoban, 2014; Atik et al., 
2015; Gurdal et al., 2013). We observed a nearly six-fold increase in synthetic cannabis usage 
from 2012 to 2013 (from 0.9% to 5.2% of inpatients), suggesting that bonzai is continuing its 
upward trend due to its promise of a stronger high, affordability, accessibility as it can be 
purchased online, and concealment of use since such usage will not create positive toxicological 
test results (Atik et al., 2015; Gurdal et al., 2013).  
Schooling and Homelessness 
In adjusted models of AMATEM inpatients (Table 3), individuals who received 
schooling for more than twelve years were more likely to inject than those with lesser education 
(adjusted odds ratio of 1.74). 40% of those reporting ever injecting had an education of 12 years 
or greater. This finding is converse to other studies that report greater proportions of PWID 
among those who have not completed secondary school and did not seek higher education 
(Abelson et al., 2006; Chikovani et al., 2011; Latimer et al., 2009; Reyes et al., 2006). PWID 
may be influenced by difficulties in finding heroin, as injection allows for a convenient and 
efficient means of getting high (Kuo et al., 2007; Todd et al., 2009). However, further research is 
needed to understand why injection may be the choice approach for the more educated in 
Turkey.  
The homeless, albeit a small group comprising about 0.2% of inpatients (Table 1), were 
at highest risk for injecting among the sample (odds ratio of 3.68 in AMATEMS), illustrating the 
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particular needs of this group. In a study conducted amongst homeless people aged 14 to 26 in 
Canada, a relationship was observed between perceived increased drug use and loss of housing 
(Cheng et al., 2014). Additionally, research in London among 1,000 homeless individuals 
reported that 88% were using at least one drug (Neale, 2008). In a study of homeless adolescents 
in Turkey, only 17% reported knowing that substance use could lead to increased risks like 
HIV/AIDS, further illustrating that knowledge on the risks of injection is scarce and outreach as 
well as health education would be beneficial for homeless populations within Turkey (Baybuga 
& Celik, 2004).  
Locational Differences 
The locations that reported the highest rates of PWID were the Marmara and 
Mediterranean regions with 33.4% at Marmara AMATEMs and 59.9% at Mediterranean 
AMATEMs vs. 26.5% at Marmara private clinics (Tables 3 & 4). Due to the limited data on 
private clinics, we only have locations from the Marmara and Southeast Anatolia regions. 54.2% 
of the youngest inpatients, 11-17 year olds, were from the Marmara region, indicating that early-
age prevention efforts may be particularly needed in this area (Table 2). The Mediterranean 
region had a high percentage of patients that injected (59.9%), with the highest percentage 
among patients of the Adana AMATEM (63.9%). These regions may see higher rates of PWID 
because of the Balkan Route, a drug trafficking path for heroin that originates in Afghanistan and 
passes through the Marmara and Mediterranean regions (EMCDDA, 2015). In tandem, the most 
populated cities in Turkey are located in the Marmara and Mediterranean regions-- Istanbul, 
Izmir, Antalya and Mersin. It has also been reported that although the Marmara and 
Mediterranean regions are considered some of the wealthiest locations in Turkey due to tourism 
and geographic location as port cities, both localities have some of the largest income 
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inequalities which can be linked to increased risk for drug use (Galea et al., 2003; Rhodes, 2009; 
Pickett & Wilkinson, 2010; Baumann et al., 2007). Further research is needed to understand 
whether these regions simply offer the most services and thus cater to higher numbers of 
patients, have higher intake due to patients traveling from other regions of Turkey that do not 
have treatment facilities, or whether these areas truly have a higher proportion of PWID.  
Relapse 
 Finally, we found that, in 2012 and 2013, about 47% of the public facility sample and 
57% of those seen in private clinics reported having received previous inpatient treatment (Table 
1). In addition, lifetime and current PWID was more common among those who had received 
previous treatment. In one study, patients who revolved in and out of treatment more than three 
times had significantly lower treatment improvement and success -- the Turkish drug users with 
previous treatment may represent a similarly challenging population (Zhang et al., 2003). 
Furthermore, treatment programs offered in Turkey focus primarily on short-term medical 
detoxification that lasts two to four weeks through the delivery of Suboxone, but do not offer 
long-term maintenance therapy and consistent follow-up (TUBIM, 2012). This further suggests 
that treatment in Turkey could be more successful if a combination of short and long-term 
offerings were available and also shaped or modified to the characteristics and needs of the 
patient.  
Limitations  
This study had several limitations. First, since the data reflect inpatients admitted to 
Turkey’s AMATEM centers and some private centers, the sample may not be representative of 
all PWUD and PWID in Turkey. Given the fact that the 22 AMATEMs are located in only 13 of 
the 81 provinces, a gap exists in Turkey’s national data for areas that host neither AMATEMs 
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nor private clinics that report to the state (TUBIM, 2012). This could cause limitations in 
understanding the demographics and drug-using behaviors of substance users, especially in 
northern and eastern areas of Turkey that lack treatment facilities. Observing only individuals in 
drug treatment also excludes drug users who are not informed about the public or private clinics, 
could not afford such help, or are not coming forward for treatment due to possible stigmas or 
cultural biases. In addition, the demographics of the private clinic inpatients were more limited, 
with some subgroups like homeless individuals not represented at all. The private clinics’ sample 
size was also limited, resulting in very wide confidence intervals. Upon intake, the patients were 
asked about their history of drug use, potentially leading to misclassification among those who 
may not accurately remember the entirety of their substance use history, like initiation and 
duration of drug use. Since this is a cross-sectional study, we cannot infer temporality between 
the correlates and initiation of PWID. Finally, we did not collect data on some potential 
predictors of injection, like exposure to PWID among friends and family members, which limits 
our ability to fully identify all characteristics associated with injection in this sample.  
Conclusion 
Despite these limitations, this study provides critical insight into the characteristics of 
inpatient PWUD in Turkey and the correlates of PWID in this population. The young age at 
which Turkish inpatients begin using heroin suggests a strong need for prevention and 
intervention efforts focused on the transition to heroin use and injection among youth 
populations. Additional efforts are needed to reduce synthetic drug use, like bonzai, among 
adolescents. It is critical to note that Turkey is considered a “young population” with the average 
age being 29.22 in 2010 (CIDOB, 2011). This further emphasizes the importance of interacting 
with younger PWUD so as to slow the growing rates of drug use, especially with that of bonzai 
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and heroin. Possible approaches could include opening more clinics specifically catered towards 
the needs of younger patients as well as integrating previously successful drug use prevention 
efforts in schools like that of working with at-risk groups, resistance-skills/life-skills training and 
social norms campaigns that correct misperceptions about drug use prevalence (Gottfredson & 
Wilson, 2003; Griffin et al., 2003).  
In addition, further counseling and outreach services are needed for subgroups that are 
utilizing inpatient facilities at low rates, including women, people without family, and homeless 
individuals. Further qualitative and quantitative research is needed to clarify whether the lack of 
representation of these groups among those seeking treatment reflects lower rates of drug use or 
underutilization of services. Such research will help identify specific barriers to treatment and 
how they can be overcome. Women who use drugs are an understudied subset of this vulnerable 
population and face a double stigmatization of being a woman and using drugs within Islamic 
countries (Spooner et al., 2015). Research has shown that the implementation of women only 
drug treatment facilities would be extremely beneficial for Islamic women who use drugs—
potentially allowing for increased access rates and improved treatment care levels (Prendergast et 
al., 2011; Ashley et al, 2003).  
Additionally, the regional differences we identified, including high levels of PWID in the 
Mediterranean region, suggest that treatment programs could begin to offer counseling, detox 
methods geared towards harder drugs, and long-term maintenance therapy to create a more 
successful program in lowering addiction to heroin and preventing relapse in these areas.   
Finally, as per regulation by Turkey’s Ministry of Health, all substance use treatment facilities, 
may they be outpatient or inpatient, must be affiliated and working under local hospital 
administration. Due to this regulation, it can be difficult to open and operate clinics in all areas 
 23 
with need, since hospitals may not have the capacity to support treatment facilities and hospitals 
do not exist in some areas. Based on this limitation, it would be advisable to consider the 
creation of freestanding outpatient treatment facilities so as to increase available services. 
Moreover, since AMATEMs are located in only certain areas of Turkey, there is a great need, 
especially in the eastern and northern parts of Turkey, to conduct population studies of PWUD so 
these locales can be properly represented and their substance use patterns, demographics, and 
behaviors can be better understood. 
This overview assists in identifying certain populations and types of drug-using behaviors 
that are associated with higher risks for injection drug use in Turkey. Such information can be 
used to better improve service delivery and develop targeted interventions as well as outreach 
efforts for those at greatest risk of injection drug use. It is ever important to identify barriers to 
drug addiction treatment and associated qualitative predictors of drug using behaviors so that 
currently increasing trends in harmful drug use in Turkey can be reversed and treatment efforts 
can be expanded.  
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FIGURE 1 – MAP OF TURKEY  
 
 
FIGURE 2- HIV/AIDS 1985 TO 2014 
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FIGURE 3- ROUTE OF TRANSMISSION 2013 
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FIGURE 4 – CLINICS BY REGION 
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TABLE APPENDIX  
 
TABLE 1 
 
Socio-demographic characteristics, drug use behaviors, and treatment history of individuals receiving inpatient drug treatment in 
AMATEMs and private clinics in Turkey, 2012-2013 
 
 
AMATEMs 
 
Private clinics 
 
2012 
 
2013 
 
Total 
 
Total 
 
n = 4586 
 
n = 6661 
 
n = 11247 
 
n = 663 
  n % 
 
n % 
 
n % 
 
n % 
Socio-demographic characteristics 
          Gender 
               Female 271 6.0 
 
362 5.4 
 
637 5.7 
 
64 9.7 
    Male 4311 94.0 
 
6299 94.6 
 
10610 94.3 
 
599 90.4 
Age 
               11-17 years 356 7.8 
 
472 7.1 
 
828 7.4 
 
87 13.1 
    18-29 years 2892 63.1 
 
4508 67.7 
 
7400 65.8 
 
377 56.9 
    30-39 years 979 21.4 
 
1279 19.2 
 
2258 20.1 
 
143 21.6 
    ≥ 40 years 359 7.8 
 
402 6.0 
 
761 6.8 
 
56 8.5 
Mean age (SD) 27.0 (8.4) 
 
26.3 (7.5) 
 
26.6 (7.9) 
 
26.3 (8.7) 
Living situation 
               Alone 236 5.2 
 
157 2.4 
 
393 3.5 
 
17 2.6 
    With family 4255 92.8 
 
6391 96.0 
 
10646 94.7 
 
642 96.8 
    With friends 20 0.4 
 
17 0.3 
 
37 0.3 
 
4 0.6 
    In a shelter 61 1.3 
 
86 1.3 
 
147 1.3 
 
0 0.0 
    Homeless 14 0.3 
 
9 0.1 
 
23 0.2 
 
0 0.0 
Employment 
               Regular job 1366 29.8 
 
1880 28.2 
 
3246 28.9 
 
303 45.7 
    Temporal employee 331 7.2 
 
0 0.0 
 
331 2.9 
 
0 0.0 
    Unemployed 2730 59.5 
 
4507 67.7 
 
7237 64.4 
 
317 47.8 
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    Unknown 159 3.5 
 
274 4.1 
 
433 3.9 
 
43 6.5 
Education 
               No formal schooling 111 2.4 
 
125 1.9 
 
236 2.1 
 
7 1.1 
    1-5 years 1276 27.8 
 
1751 26.3 
 
3027 26.9 
 
125 18.9 
    6-8 years 1992 43.4 
 
2855 42.9 
 
4847 43.1 
 
295 44.5 
    9-12 years 993 21.7 
 
1641 24.6 
 
2634 23.4 
 
186 28.1 
    > 12 years 214 4.7 
 
289 4.3 
 
503 4.5 
 
50 7.5 
Region 
               Marmara 1716 37.4 
 
2659 39.9 
 
4375 38.9 
 
551 83.1 
    Aegean 377 8.2 
 
542 8.1 
 
919 8.2 
 
0 0.0 
    Mediterranean 1874 40.9 
 
2371 35.6 
 
4245 37.7 
 
0 0.0 
    Central Anatolia 257 5.6 
 
697 10.5 
 
954 8.5 
 
0 0.0 
    Southeast Anatolia 29 0.6 
 
47 0.7 
 
76 0.7 
 
112 16.9 
    Black Sea Region 111 2.4 
 
98 1.5 
 
209 1.9 
 
0 0.0 
    East Anatolia 222 4.8 
 
247 3.7 
 
469 4.2 
 
0 0.0 
Drug use behaviors 
           Preferred drug 
               Heroin 3413 74.4 
 
5068 76.1 
 
8481 75.4 
 
418 63.1 
    Other opiates 42 0.9 
 
88 1.3 
 
130 1.2 
 
9 1.4 
    Cocaine 73 1.6 
 
57 0.9 
 
130 1.2 
 
27 4.1 
    Cannabis 676 14.7 
 
809 12.2 
 
1485 13.2 
 
122 18.4 
    Synthetic cannabis 43 0.9 
 
345 5.2 
 
388 3.5 
 
46 6.9 
    Club drugs 54 1.2 
 
54 0.8 
 
108 1.0 
 
6 0.9 
    Prescription medications 61 1.3 
 
50 0.8 
 
111 1.0 
 
4 0.6 
    Inhalants 224 4.9 
 
190 2.9 
 
414 3.7 
 
31 4.7 
Mean age at first drug use (SD) 19.8 (6.4) 
 
19.5 (5.7) 
 
19.6 (6.0) 
 
19.6 (6.6) 
Duration of drug use 
               ≤ 2 years 804 17.5 
 
1321 19.8 
 
2125 18.9 
 
161 24.3 
    3-5 years 1547 33.7 
 
2266 34.0 
 
3813 33.9 
 
210 31.7 
    6-9 years 1059 23.1 
 
1572 23.6 
 
2631 23.4 
 
140 21.1 
    ≥ 10 years 1176 25.6 
 
1502 22.6 
 
2678 23.8 
 
152 22.9 
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Frequency of drug use 
               Every day 4456 97.2 
 
6655 99.9 
 
11111 98.8 
 
660 99.6 
    2-6 days per week 98 2.1 
 
5 0.1 
 
103 0.9 
 
3 0.5 
    1 day per week or less 32 0.7 
 
1 0.02 
 
33 0.3 
 
0 0.0 
Used multiple drug types in past month 
              No 2993 65.3 
 
4655 69.9 
 
7648 68.0 
 
426 64.3 
    Yes 1593 34.7 
 
2006 30.1 
 
3599 32.0 
 
237 35.8 
Preferred route of administration 
               Inject 1706 37.2 
 
2088 31.4 
 
3794 33.7 
 
120 18.1 
    Smoke 1121 24.4 
 
1292 19.4 
 
2413 21.5 
 
172 25.9 
    Snort 1635 35.7 
 
3136 47.1 
 
4771 42.4 
 
361 54.5 
    Eat or Drink 124 2.7 
 
145 2.2 
 
269 2.4 
 
10 1.5 
Mean age at first injection (SD)a 23.1 (5.8) 
 
23.0 (5.5) 
 
23.0 (5.6) 
 
22.4 (5.4) 
Treatment History 
           Previous drug treatment 
               No 2471 53.9 
 
3468 52.1 
 
5939 52.8 
 
285 43.0 
    Yes 2115 46.1   3193 47.9   5308 47.2   378 57.0 
a Among those who ever injected drugs 
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TABLE 2  
 
Socio-demographic characteristics, drug use behaviors, and treatment history of individuals receiving inpatient drug treatment in 
AMATEMs in Turkey in 2012-2013, by age category (n = 11,247) 
 
 
Age 11-17 years 
 
Age 18-29 years 
 
Age 30-39 years 
 
Age ≥ 40 years 
 
 
n = 828 
 
n = 7400 
 
n = 2258 
 
n = 761 
   n % 
 
n % 
 
n % 
 
n % p-valueb 
Socio-demographic characteristics 
            Gender 
                Female 156 18.8 
 
363 4.9 
 
91 4.0 
 
27 3.6 <0.001 
    Male 672 81.2 
 
7037 95.1 
 
2167 96.0 
 
734 96.5 
 Living situation 
                Alone 1 0.1 
 
174 2.4 
 
120 5.3 
 
98 12.9 <0.001 
    With family 754 91.1 
 
7119 96.2 
 
2120 93.9 
 
653 85.8 
     With friends 2 0.2 
 
21 0.3 
 
11 0.5 
 
3 0.4 
     In a shelter 71 8.6 
 
73 1.0 
 
1 0.04 
 
2 0.3 
     Homeless 0 0.0 
 
12 0.2 
 
6 0.3 
 
5 0.7 
 Employment 
                Regular job 84 10.1 
 
2073 28.0 
 
851 37.7 
 
238 31.3 <0.001 
    Temporal employee 5 0.6 
 
216 2.9 
 
88 3.9 
 
22 2.9 
     Unemployed 626 75.6 
 
4860 65.7 
 
1312 58.1 
 
439 57.7 
     Unknown 113 13.7 
 
251 3.4 
 
7 0.3 
 
62 8.2 
 Education 
                No formal schooling 8 1.0 
 
154 2.1 
 
48 2.1 
 
26 3.4 <0.001 
    1-5 years 151 18.2 
 
1630 22.0 
 
911 40.4 
 
335 44.0 
     6-8 years 552 66.7 
 
3404 46.0 
 
679 30.1 
 
212 27.9 
     9-12 years 114 13.8 
 
1895 25.6 
 
490 21.7 
 
135 17.7 
     > 12 years 3 0.4 
 
317 4.3 
 
130 5.8 
 
53 7.0 
 Region 
                Marmara 449 54.2 
 
2754 37.2 
 
881 39.0 
 
291 38.2 <0.001 
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    Aegean 83 10.0 
 
565 7.6 
 
190 8.4 
 
81 10.6 
     Mediterranean 102 12.3 
 
3077 41.6 
 
858 38.0 
 
208 27.3 
     Central Anatolia 113 13.7 
 
627 8.5 
 
148 6.6 
 
66 8.7 
     Southeast Anatolia 74 8.9 
 
2 0.03 
 
0 0.0 
 
0 0.0 
     Black Sea Region 5 0.6 
 
116 1.6 
 
59 2.6 
 
29 3.8 
     East Anatolia 2 0.2 
 
259 3.5 
 
122 5.4 
 
86 11.3 
 Drug use behaviors 
            Preferred drug 
                Heroin 346 41.8 
 
5926 80.1 
 
1656 73.3 
 
553 72.7 <0.001 
    Other opiates 1 0.1 
 
54 0.7 
 
50 2.2 
 
25 3.3 
     Cocaine 0 0.0 
 
55 0.7 
 
60 2.7 
 
15 2.0 
     Cannabis 245 29.6 
 
829 11.2 
 
311 13.8 
 
100 13.1 
     Synthetic cannabis 62 7.5 
 
250 3.4 
 
70 3.1 
 
6 0.8 
     Club drugs 26 3.1 
 
61 0.8 
 
17 0.8 
 
4 0.5 
     Prescription medications 1 0.1 
 
18 0.2 
 
40 1.8 
 
52 6.8 
     Inhalants 147 17.8 
 
207 2.8 
 
54 2.4 
 
6 0.8 
 Mean age at first drug use (SD) 13.7 (1.7) 
 
18.1 (3.7) 
 
23.5 (5.9) 
 
29.1 (10.0) <0.001 
Duration of drug use 
                ≤ 2 years 431 52.1 
 
1442 19.5 
 
216 9.6 
 
36 4.7 <0.001 
    3-5 years 355 42.9 
 
2948 39.8 
 
435 19.3 
 
75 9.9 
     6-9 years 40 4.8 
 
2025 27.4 
 
490 21.7 
 
76 10.0 
     ≥ 10 years 2 0.2 
 
985 13.3 
 
1117 49.5 
 
574 75.4 
 Frequency of drug use 
                Every day 786 94.9 
 
7341 99.2 
 
2232 98.9 
 
752 98.8 <0.001 
    2-6 days per week 30 3.6 
 
47 0.6 
 
19 0.8 
 
7 0.9 
     1 day per week or less 12 1.5 
 
12 0.2 
 
7 0.3 
 
2 0.3 
 Used multiple drug types in past month 
               No 413 49.9 
 
5018 67.8 
 
1614 71.5 
 
603 79.2 <0.001 
    Yes 415 50.1 
 
2382 32.2 
 
644 28.5 
 
158 20.8 
 Preferred route of administration 
                Inject 87 10.5 
 
2683 36.3 
 
831 36.8 
 
193 25.4 <0.001 
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    Smoke 343 41.4 
 
1448 19.6 
 
472 20.9 
 
150 19.7 
     Snort 371 44.8 
 
3164 42.8 
 
878 38.9 
 
358 47.0 
     Eat or Drink 27 3.3 
 
105 1.4 
 
77 3.4 
 
60 7.9 
 Mean age at first injection (SD)a 15.2 (1.4) 
 
21.2 (3.3) 
 
27.2 (5.0) 
 
33.0 (8.7) <0.001 
Treatment History 
            Previous drug treatment 
                No 626 75.6 
 
4096 55.4 
 
968 42.9 
 
249 32.7 <0.001 
    Yes 202 24.4   3304 44.7   1290 57.1   512 67.3   
a Among those who ever injected drugs 
b p-value from Chi-square test for categorical variables and ANOVA for continuous variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
TABLE 3  
 
Correlates of lifetime and current injection drug use among individuals receiving inpatient drug treatment in AMATEMs in Turkey in 
2012-2013 (n = 11,247) 
 
 
Lifetime injection drug use 
 
Current injection drug use 
  
n ever 
injected 
% ever 
injected p-value 
 
Adjusted OR  
(95% CI) 
 
n 
injected 
in past 
30 days 
% 
injected 
in past 
30 days p-value 
 
Adjusted OR  
(95% CI) 
Total 4545 40.4 
     
3794 33.7 
    Socio-demographic 
characteristics 
             Gender 
                 Female 197 30.9 <0.001 
 
1.00 (ref) 
 
141 22.1 <0.001 
 
1.00 (ref) 
    Male 4348 41.0 
  
1.04 (0.84 - 1.29) 
 
3653 34.4 
  
1.25 (1.00 - 1.56) 
Age 
                 11-17 years 120 14.5 <0.001 
 
1.00 (ref) 
 
87 10.5 <0.001 
 
1.00 (ref) 
    18-29 years 3151 42.6 
  
1.27 (1.00 - 1.61) 
 
2683 36.3 
  
1.34 (1.03 - 1.74) 
    30-39 years 1008 44.6 
  
1.26 (0.96 - 1.64) 
 
831 36.8 
  
1.19 (0.89 - 1.59) 
    ≥ 40 years 266 35.0 
  
0.66 (0.48 - 0.90) 
 
193 25.4 
  
0.57 (0.40 - 0.80) 
Living situation 
                 Alone 167 42.5 0.005 
 
1.00 (ref) 
 
144 36.6 <0.001 
 
1.00 (ref) 
    With family 4307 40.5 
  
0.78 (0.60 - 1.01) 
 
3595 33.8 
  
0.72 (0.56 - 0.93) 
    With friends 18 48.7 
  
1.53 (0.68 - 3.41) 
 
16 43.2 
  
1.70 (0.77 - 3.78) 
    In a shelter 40 27.2 
  
1.46 (0.83 - 2.58) 
 
27 18.4 
  
1.02 (0.56 - 1.86) 
    Homeless 13 56.5 
  
3.68 (1.14 - 11.89) 
 
12 52.2 
  
3.84 (1.23 - 12.00) 
Employment 
                 Regular job 1200 37.0 <0.001 
 
1.00 (ref) 
 
996 30.7 <0.001 
 
1.00 (ref) 
    Temporal employee 163 49.2 
  
1.31 (1.00 - 1.71) 
 
147 44.4 
  
1.41 (1.08 - 1.84) 
    Unemployed 3067 42.4 
  
1.18 (1.07 - 1.31) 
 
2572 35.5 
  
1.16 (1.05 - 1.29) 
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    Unknown 115 26.6 
  
1.27 (0.95 - 1.71) 
 
79 18.2 
  
0.98 (0.71 - 1.34) 
 
Education 
                 No formal schooling 107 45.3 <0.001 
 
1.00 (ref) 
 
95 40.3 <0.001 
 
1.00 (ref) 
    1-5 years 1354 44.7 
  
1.21 (0.89 - 1.65) 
 
1148 37.9 
  
1.12 (0.82 - 1.53) 
    6-8 years 1814 37.4 
  
1.07 (0.78 - 1.45) 
 
1502 31.0 
  
0.99 (0.73 - 1.34) 
    9-12 years 1041 39.5 
  
1.24 (0.90 - 1.69) 
 
857 32.5 
  
1.14 (0.83 - 1.55) 
    > 12 years 229 45.5 
  
1.72 (1.19 - 2.48) 
 
192 38.2 
  
1.53 (1.06 - 2.21) 
Region 
                 Marmara 1461 33.4 <0.001 
 
1.00 (ref) 
 
1108 25.3 <0.001 
 
1.00 (ref) 
    Aegean 199 21.7 
  
0.85 (0.69 - 1.04) 
 
158 17.2 
  
0.96 (0.78 - 1.19) 
    Mediterranean 2544 59.9 
  
2.04 (1.84 - 2.25) 
 
2268 53.4 
  
2.45 (2.20 - 2.72) 
    Central Anatolia 248 26.0 
  
0.65 (0.55 - 0.78) 
 
180 18.9 
  
0.66 (0.55 - 0.80) 
    Southeast Anatolia 0 0.0 
  
n/a n/a 
 
0 0.0 
  
n/a n/a 
    Black Sea Region 18 8.6 
  
0.63 (0.36 - 1.12) 
 
16 7.7 
  
0.91 (0.51 - 1.64) 
    East Anatolia 75 16.0 
  
0.38 (0.29 - 0.50) 
 
64 13.7 
  
0.52 (0.39 - 0.70) 
Drug use behaviors 
             Heroin as preferred drug 
                 No 99 3.6 <0.001 
 
1.00 (ref) 
 
73 2.6 <0.001 
 
1.00 (ref) 
    Yes 4446 52.4 
  
22.92 (18.51 - 28.37) 
 
3721 43.9 
  
20.59 (16.12 - 26.29) 
Duration of drug use 
                 ≤ 2 years 457 21.5 <0.001 
 
1.00 (ref) 
 
384 18.1 <0.001 
 
1.00 (ref) 
    3-5 years 1513 39.7 
  
1.89 (1.65 - 2.17) 
 
1237 32.4 
  
1.67 (1.44 - 1.93) 
    6-9 years 1315 50.0 
  
2.54 (2.18 - 2.95) 
 
1137 43.2 
  
2.34 (2.00 - 2.74) 
    ≥ 10 years 1260 47.1 
  
3.12 (2.64 - 3.69) 
 
1036 38.7 
  
2.73 (2.28 - 3.27) 
Used multiple drug types in past 
month 
                No 3080 40.3 0.662 
 
-- -- 
 
2517 32.9 0.007 
 
1.00 (ref) 
    Yes 1465 40.7 
  
-- -- 
 
1277 35.5 
  
0.86 (0.77 - 0.96) 
Treatment history 
             Previous drug treatment 
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    No 1743 29.4 <0.001 
 
1.00 (ref) 
 
1447 24.4 <0.001 
 
1.00 (ref) 
    Yes 2802 52.8     1.88 (1.71 - 2.06)   2347 44.2     1.73 (1.57 - 1.90) 
  
 46 
TABLE 4 
 
Socio-demographic characteristics, drug use behaviors, and treatment history of injection drug users receiving inpatient drug treatment 
in Turkey, 2012-2013 
 
 
Ever injected drugs 
 
Injected drugs in 
past 30 days 
 
n = 4,694 
 
n = 3,914 
  n % 
 
n % 
Socio-demographic characteristics 
     Gender 
         Female 216 4.6 
 
155 4.0 
    Male 4478 95.4 
 
3759 96.0 
Age 
         11-17 years 122 2.6 
 
89 2.3 
    18-29 years 3246 69.2 
 
2763 70.6 
    30-39 years 1045 22.3 
 
858 21.9 
    ≥ 40 years 281 6.0 
 
204 5.2 
Mean age (SD) 27.2 (7.0) 
 
27.0 (6.6) 
Living situation 
         Alone 173 3.7 
 
150 3.8 
    With family 4448 94.8 
 
3707 94.7 
    With friends 20 0.4 
 
18 0.5 
    Charity 40 0.9 
 
27 0.7 
    Homeless 13 0.3 
 
12 0.3 
Employment 
         Regular job 1285 27.4 
 
1062 27.1 
    Temporal employee 163 3.5 
 
147 3.8 
    Unemployed 3125 66.6 
 
2621 67.0 
    Unknown 121 2.6 
 
84 2.2 
Education 
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    No formal schooling 109 2.3 
 
97 2.5 
    1-5 years 1388 29.6 
 
1177 30.1 
    6-8 years 1868 39.8 
 
1546 39.5 
    9-12 years 1080 23.0 
 
894 22.8 
    > 12 years 249 5.3 
 
200 5.1 
Region 
         Marmara 1607 34.2 
 
1225 31.3 
    Aegean 199 4.2 
 
158 4.0 
    Mediterranean 2544 54.2 
 
2268 58.0 
    Central Anatolia 248 5.3 
 
180 4.6 
    Southeast Anatolia 3 0.1 
 
3 0.1 
    Black Sea Region 18 0.4 
 
16 0.4 
    East Anatolia 75 1.6 
 
64 1.6 
 
Location of treatment 
         Private clinic 149 3.2 
 
120 3.1 
    Public treatment center (AMATEM) 4545 96.8 
 
3794 96.9 
Drug use behaviors 
     Drug of choice 
         Heroin 4589 97.8 
 
3835 98.0 
    Other opiates 92 2.0 
 
72 1.8 
    Other drugsa 13 0.3 
 
7 0.2 
Mean age at first drug use (SD) 20.6 (5.1) 
 
20.6 (5.0) 
Duration of drug use 
         ≤ 2 years 487 10.4 
 
411 10.5 
    3-5 years 1554 33.1 
 
1274 32.6 
    6-9 years 1342 28.6 
 
1157 29.6 
    ≥ 10 years 1311 27.9 
 
1072 27.4 
Used multiple drug types in past month 
         No 3181 67.8 
 
2591 66.2 
    Yes 1513 32.2 
 
1323 33.8 
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Mean age at first injection (SD) 23.0 (5.6) 
 
22.9 (5.5) 
Ever shared needles 
         No 1248 26.6 
 
811 20.7 
    Yes 3446 73.4 
 
3103 79.3 
Shared needles in past 30 days 
         No 2518 53.6 
 
1738 44.4 
    Yes 2176 46.4 
 
2176 55.6 
Treatment history 
     Previous drug treatment 
         No 1770 37.7 
 
1468 37.5 
    Yes 2924 62.3   2446 62.5 
a Other drugs include cannabis, synthetic cannabis, and prescription medications 
 
 
TABLE 5 
 
Prevalence of HBV, HCV, and HIV infection among injection drug users receiving inpatient drug treatment in Turkey, 2012-2013 
 
 
Ever injected drugs 
 
Injected drugs in past 30 days 
 
n = 4,477a 
 
n = 3,718a 
  n % (95% CI) 
 
n % (95% CI) 
Infection status 
           HBV-positive 276 6.2 (5.5, 6.9) 
 
219 5.9 (5.1, 6.6) 
    HCV-positive 2107 47.1 (45.6, 48.5) 
 
1930 51.9 (50.3, 53.5) 
    HIV-positive 15 0.34 (0.17, 0.50)   14 0.38 (0.18, 0.57) 
a Restricted to those with known infection status 
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TABLE 6 
Correlates of needle sharing in the past 30 days among current injection drug users receiving inpatient drug treatment in Turkey (n = 
3,718)a 
 
Shared needles in past 30 days 
  n 
% 
shared 
needles p-value 
 
Unadjusted 
OR (95% CI) 
 
Adjusted 
OR (95% CI) 
Total 2073 55.8 
       Socio-demographic characteristics 
         Gender 
             Female 76 51.7 0.313 
 
1.00 (ref) 
 
-- -- 
    Male 1997 55.9 
  
1.19 (0.85 - 1.65) 
 
-- -- 
Age 
             11-17 years 54 62.8 <0.001 
 
2.48 (1.47 - 4.18) 
 
2.12 (1.19 - 3.79) 
    18-29 years 1546 58.3 
  
2.06 (1.52 - 2.77) 
 
1.74 (1.23 - 2.46) 
    30-39 years 396 50.0 
  
1.47 (1.06 - 2.02) 
 
1.26 (0.89 - 1.77) 
    ≥ 40 years 77 40.5 
  
1.00 (ref) 
 
1.00 (ref) 
Living situation 
             Alone 69 50.7 0.544 
 
1.00 (ref) 
 
-- -- 
    With family 1973 55.9 
  
1.23 (0.88 - 1.74) 
 
-- -- 
    With friends 7 43.8 
  
0.76 (0.27 - 2.14) 
 
-- -- 
    Charity 16 59.3 
  
1.41 (0.61 - 3.27) 
 
-- -- 
    Homeless 8 66.7 
  
1.94 (0.56 - 6.75) 
 
-- -- 
Employment 
             Regular job 503 50.1 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    Temporal employee 85 66.9 
  
2.02 (1.37 - 2.98) 
 
1.63 (1.10 - 2.43) 
    Unemployed 1439 57.5 
  
1.35 (1.16 - 1.56) 
 
1.22 (1.05 - 1.43) 
    Unknown 46 56.1 
  
1.28 (0.81 - 2.01) 
 
1.57 (0.97 - 2.55) 
Education 
             No formal schooling 69 75.0 <0.001 
 
5.30 (3.04 - 9.26) 
 
3.82 (2.16 - 6.76) 
    1-5 years 653 58.8 
  
2.52 (1.83 - 3.47) 
 
2.01 (1.44 - 2.81) 
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    6-8 years 842 57.4 
  
2.38 (1.74 - 3.25) 
 
1.93 (1.39 - 2.68) 
    9-12 years 440 51.4 
  
1.87 (1.35 - 2.59) 
 
1.59 (1.13 - 2.23) 
    > 12 years 69 36.1 
  
1.00 (ref) 
 
1.00 (ref) 
Region 
             Marmara 629 53.2 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    Aegean 45 28.9 
  
0.36 (0.25 - 0.51) 
 
0.36 (0.25 - 0.53) 
    Mediterranean 1294 60.7 
  
1.36 (1.18 - 1.57) 
 
1.14 (0.97 - 1.34) 
    Central Anatolia 74 41.1 
  
0.61 (0.45 - 0.84) 
 
0.58 (0.42 - 0.81) 
    Southeast Anatolia 3 100.0 
  
n/a n/a 
 
n/a n/a 
    Black Sea Region 4 25.0 
  
0.29 (0.09 - 0.92) 
 
0.43 (0.13 - 1.44) 
    East Anatolia 24 48.0 
  
0.81 (0.46 - 1.43) 
 
0.79 (0.44 - 1.41) 
Location of treatment 
             Private clinic 46 42.6 0.005 
 
1.00 (ref) 
 
1.00 (ref) 
    Public treatment center (AMATEM) 2027 56.2 
  
1.73 (1.17 - 2.54) 
 
1.60 (1.05 - 2.44) 
Drug use behaviors 
         Heroin as drug of choice 
             No 10 13.7 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    Yes 2063 56.6 
  
8.21 (4.20 - 16.05) 
 
4.83 (2.42 - 9.64) 
Duration of drug use 
             ≤ 2 years 208 53.3 0.046 
 
1.00 (ref) 
 
1.00 (ref) 
    3-5 years 664 54.6 
  
1.05 (0.84 - 1.32) 
 
0.99 (0.78 - 1.26) 
    6-9 years 652 59.3 
  
1.27 (1.01 - 1.61) 
 
1.21 (0.94 - 1.55) 
    ≥ 10 years 549 54.3 
  
1.04 (0.82 - 1.31) 
 
1.18 (0.90 - 1.55) 
Used multiple drug types in past month 
             No 1341 54.3 0.014 
 
1.00 (ref) 
 
1.00 (ref) 
    Yes 732 58.6 
  
1.19 (1.04 - 1.36) 
 
1.01 (0.86 - 1.18) 
Treatment history 
         Previous drug treatment 
             No 767 55.9 0.859 
 
1.00 (ref) 
 
-- -- 
    Yes 1306 55.7     0.99 (0.86 - 1.13)   -- -- 
a Restricted to those with known infection status 
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TABLE 7 
 
Correlates of HCV infection among current injection drug users receiving inpatient drug treatment in Turkey (n = 3,718)a 
 
HCV-positive 
  n % HCV+ p-value 
 
Unadjusted 
OR (95% CI) 
 
Adjusted 
OR (95% CI) 
Total 1930 51.9 
       Socio-demographic characteristics 
         Gender 
             Female 56 38.1 <0.001
 
1.00 (ref)
 
1.00 (ref)
    Male 1874 52.5 
  
1.79 (1.28 - 2.52) 
 
1.09 (0.75 - 1.59) 
Age 
             11-17 years 30 34.9 <0.001
 
1.00 (ref)
 
1.00 (ref)
    18-29 years 1325 50.0 
  
1.87 (1.19 - 2.93) 
 
1.21 (0.73 - 2.01) 
    30-39 years 452 57.1 
  
2.48 (1.56 - 3.95) 
 
1.48 (0.87 - 2.54) 
    ≥ 40 years 123 64.7 
  
3.43 (2.01 - 5.85) 
 
2.48 (1.32 - 4.65) 
Living situation 
             Alone 84 61.8 0.001
 
1.00 (ref)
 
1.00 (ref)
    With family 1825 51.7 
  
0.66 (0.47 - 0.94) 
 
0.72 (0.48 - 1.08) 
    With friends 2 12.5 
  
0.09 (0.02 - 0.41) 
 
0.18 (0.04 - 0.88) 
    Charity 11 40.7 
  
0.43 (0.18 - 0.99) 
 
0.77 (0.28 - 2.18) 
    Homeless 8 66.7 
  
1.24 (0.36 - 4.32) 
 
1.19 (0.30 - 4.66) 
Employment 
             Regular job 498 49.6 0.007 
 
1.00 (ref) 
 
1.00 (ref) 
    Temporal employee 69 54.3 
  
1.21 (0.84 - 1.75) 
 
0.77 (0.51 - 1.14) 
    Unemployed 1333 53.2 
  
1.16 (1.00 - 1.34) 
 
1.04 (0.88 - 1.22) 
    Unknown 30 36.6 
  
0.59 (0.37 - 0.94) 
 
0.76 (0.43 - 1.35) 
Education 
             No formal schooling 56 60.9 <0.001
 
2.07 (1.25 - 3.43)
 
1.24 (0.72 - 2.16)
    1-5 years 644 58.0 
  
1.83 (1.34 - 2.50) 
 
1.33 (0.94 - 1.87) 
    6-8 years 733 49.9 
  
1.33 (0.98 - 1.80) 
 
1.27 (0.91 - 1.78) 
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    9-12 years 415 48.5 
  
1.25 (0.91 - 1.72) 
 
1.34 (0.95 - 1.90) 
    > 12 years 82 42.9 
  
1.00 (ref) 
 
1.00 (ref) 
Region 
             Marmara 437 37.0 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    Aegean 55 35.3 
  
0.93 (0.66 - 1.32) 
 
1.05 (0.72 - 1.55) 
    Mediterranean 1357 63.7 
  
2.99 (2.58 - 3.46) 
 
3.21 (2.72 - 3.79) 
    Central Anatolia 56 31.1 
  
0.77 (0.55 - 1.08) 
 
0.84 (0.59 - 1.20) 
    Southeast Anatolia 3 100.0 
  
n/a n/a 
 
n/a n/a 
    Black Sea Region 6 37.5 
  
1.02 (0.37 - 2.83) 
 
1.33 (0.41 - 4.26) 
    East Anatolia 16 32.0 
  
0.80 (0.44 - 1.47) 
 
0.61 (0.32 - 1.15) 
Location of treatment 
             Private clinic 54 50.0 0.687 
 
1.00 (ref) 
 
-- -- 
    Public treatment center (AMATEM) 1876 52.0 
  
1.08 (0.74 - 1.59) 
 
-- -- 
Drug use behaviors 
         Heroin as drug of choice 
             No 15 20.6 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    Yes 1915 52.5 
  
4.28 (2.42 - 7.58) 
 
2.35 (1.27 - 4.36) 
Duration of drug use 
             ≤ 2 years 129 33.1 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    3-5 years 569 46.8 
  
1.78 (1.40 - 2.26) 
 
1.49 (1.15 - 1.93) 
    6-9 years 598 54.4 
  
2.41 (1.89 - 3.07) 
 
1.70 (1.30 - 2.23) 
    ≥ 10 years 634 62.7 
  
3.39 (2.65 - 4.34) 
 
2.26 (1.67 - 3.05) 
Used multiple drug types in past month 
             No 1231 49.9 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    Yes 699 55.9 
  
1.28 (1.11 - 1.46) 
 
0.77 (0.65 - 0.92) 
Shared needles in past 30 days 
             No 691 42.0 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
    Yes 1239 59.8 
  
2.05 (1.80 - 2.34) 
 
1.99 (1.72 - 2.30) 
Treatment history 
         Previous drug treatment 
             No 556 40.6 <0.001 
 
1.00 (ref) 
 
1.00 (ref) 
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    Yes 1374 58.5 
  
2.07 (1.81 - 2.37) 
 
1.97 (1.70 - 2.29) 
 
Infection status 
         HBV-positive 
             No 1811 51.8 0.459 
 
1.00 (ref) 
 
-- -- 
    Yes 119 54.3 
  
1.11 (0.84 - 1.46) 
 
-- -- 
HIV-positive 
             No 1923 51.9 0.886 
 
1.00 (ref) 
 
-- -- 
    Yes 7 50.0     0.93 (0.32 - 2.65)   -- -- 
a Restricted to those with known infection status
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